ScienceDex / Researcher record
Swee Lay Thein
- National Heart, Lung, and Blood Institute (no department on record)
From the FY2025 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 10% Funded
- Early Career
NIH Funding · FY2025
Award data coverage
One fiscal year is available for this record. This does not establish the first NIH award or current employer.
Single fiscal year on record (FY2025): $4.6M in linked award amounts across 9 award records · Award-linked rank #1658.
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY2025 · selected9 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 15233859Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2025 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2025 award records by amount
NIH award records listing Swee Lay Thein as a PI. Multi-PI records show the full award amount for context.
- 1ZIAHL006233-09ZIAContact PIStudies of the Natural History of Sickle Cell Disease$958.1Kaward amount
- 1ZIAHL006241-07ZIAContact PIHuman Specimen Collection to Support Basic and Clinical Research$775.6Kaward amount
- 1ZIAHL006296-03ZIAContact PIObservational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease$684.3Kaward amount
- 1ZIAHL006240-07ZIAContact PIGenotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease$684.3Kaward amount
- 1ZIAHL006284-03ZIAContact PIA Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with stable sickle cell disease$684.3Kaward amount
- 1ZIAHL006266-05ZIAContact PIEvaluation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of long-term mitapivat dosing in subjects with stable sickle cell disease$456.2Kaward amount
- 1ZIAHL006282-02ZIAContact PIA Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease$228.1Kaward amount
- 1ZIAHL006283-03ZIAContact PIExploring Near Infrared Spectroscopy (NIRS) technologies for assessment of muscle physiology, tissue oxygenation, and blood flow in patients with Sickle Cell Disease (SCD$45.6Kaward amount
- 1ZIAHL006239-07ZIAContact PIA Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of escalating multiple oral doses of AG-348 in subjects with stable sickle cell disease$45.6Kaward amount
Award organization
Organizations that administered FY2025 awards listing Swee Lay Thein as a PI.
FY2025 award administered by National Heart, Lung, and Blood Institute ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2025First NIH AwardNational Heart, Lung, and Blood Institute
- 2025$500K Cumulative Funding
- 2025$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #1658
- 2025Entered Top 25% NationallyRanked #1658
- 2025Entered Top 10% NationallyRanked #1658